TWM
SRNE

Thrive Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Thrive Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,146
Closed -$17K – 171
2022
Q3 		$17K Hold
11,146
– – 0.01% 147
2022
Q2 		$22K Hold
11,146
– – 0.01% 147
2022
Q1 		$26K Hold
11,146
– – 0.01% 155
2021
Q4 		$52K Buy
+11,146
New +$69.2K 0.02% 144

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Thrive Wealth Management's SRNE Position: Q4 2022 in Review

Thrive Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 11,146 shares — an estimated $17K sold.

Thrive Wealth Management first reported a position in SRNE in Q4 2021 and held it in 4 quarters. The position peaked at $52K in Q4 2021. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

  • Thrive Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Thrive Wealth Management sold 11,146 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $17K.
  • Thrive Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 4 quarters.
  • Thrive Wealth Management's Sorrento Therapeutics, Inc. position peaked at $52K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Thrive Wealth Management's 13F filing for Q4 2022, filed 25 Jan 2023.